Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Prostate Cancer Screening With Abbreviated MRI Protocol

A legfontosabb adatok

Ki végzi
Masaryk Memorial Cancer Institute
Hol
Csehország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
300 fő, tervezett
Kezdés
2022. máj. 1.
Várható befejezés
2026. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • magnetic resonance
  • serum PSA examination
  • Biopsy
A regiszteradat frissítve
2026. november 10.

Ki vehet részt

Életkor
50 év – 69 év
Nem
Csak férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 50-69 years
  • Life expectancy over 10 years
  • Ability to undergo all planned procedures (without contraindications to MRI or biopsy)
  • No known prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction)
  • No PSA test or prostate MRI in the past 2 years
  • No signs of prostatitis or urinary tract infection in the past 6 months
  • Signed informed consent

Ki nem vehet részt

  • Contraindications to MRI
  • Hip replacement
  • Known BRCA1/BRCA2 mutation

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Prostate cancer is one of the most common malignancies in the male population with incidence and mortality rates comparable to breast cancer in women, but in contrast, a population screening program that would fulfill all the recommended criteria is not yet available. According to international recommendations, the preventive PSA sampling used in clinical practice is not suitable because of the concurrent detection of clinically insignificant carcinomas in a major proportion of tests. These clinically non-significant cancers make up a significant and increasing proportion with age. Detection of non-significant cancers burdens the health care system and patients with the care that has no positive impact on their health. Current preventive serum prostate-specific antigen (PSA) testing does not distinguish benign hyperplasia and nonsignificant carcinoma from clinically significant cancer. It is therefore not suitable for full-scale screening.

A teljes eredeti leírásKevesebb

According to current guidelines, magnetic resonance imaging (MRI) is indicated only in patients with an increased risk of cancer for detection or staging after biopsy and is not used for screening. According to recent studies, MRI has detected an increased proportion of significant cancers in the general population compared to screening based on PSA, while fewer clinically insignificant cancers have been detected. In screening, a shorter examination protocol without contrast medium (biparametric MRI) is used with a lower cost per examination, allowing to increase both the number of patients examined and patient comfort.

The main objective of the project is to assess the contribution of imaging in the screening of clinically significant prostate cancer and to validate the published results in the Czech population, and extend the screening model by the second round of examinations and additional laboratory markers. The secondary aim is to design a subsequent study with a larger number of participants allowing statistical evaluation, similar to the successful breast cancer screening.

A vizsgálat csoportja

  • Preventive prostate examination by bpMRIA vizsgált kezelés

    The cohort consists of patients: * with age 50-69 years * without any contraindications to MRI or biopsy * without known status of prostate cancer or prostate biopsy in the past (interventions for BPH are not a restriction) * without known BRCA mutation * without PSA test or prostate MRI in the past 2 years * without any signs of prostatitis or urinary tract infection in the past 6 months.

    Kezelés: magnetic resonance, serum PSA examination és Biopsy

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
ProstaPilot: Prostate Cancer Screening Using MRI With an Abbreviated Protocol
Publikációk
A regiszteradat frissítve
2026. november 10.